−3.70USD
−214.53 MUSD
4.01 MUSD
72.14 M
About Crinetics Pharmaceuticals, Inc.
Sector
CEO
Scott R. Struthers
Headquarters
San Diego
Website
Employees (FY)
290
Founded
2008
ISIN
US22663K1079
FIGI
BBG00BC59224
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CRNX is 42.97 USD — it has decreased by 0.09% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Crinetics Pharmaceuticals, Inc. stocks are traded under the ticker CRNX.
Crinetics Pharmaceuticals, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
CRNX stock is 4.86% volatile and has beta coefficient of 1.00. Check out the list of the most volatile stocks — is Crinetics Pharmaceuticals, Inc. there?
One year price forecast for Crinetics Pharmaceuticals, Inc. has a max estimate of 80.00 USD and a min estimate of 40.00 USD.
CRNX earnings for the last quarter are −1.01 USD per share, whereas the estimation was −0.87 USD resulting in a −16.49% surprise. The estimated earnings for the next quarter are −0.86 USD per share. See more details about Crinetics Pharmaceuticals, Inc. earnings.
Crinetics Pharmaceuticals, Inc. revenue for the last quarter amounts to 346.00 K USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 197.10 K USD.
Yes, you can track Crinetics Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
CRNX stock has fallen by 10.01% compared to the previous week, the month change is a 2.85% fall, over the last year Crinetics Pharmaceuticals, Inc. has showed a 155.47% increase.
CRNX net income for the last quarter is −60.10 M USD, while the quarter before that showed −57.46 M USD of net income which accounts for −4.59% change. Track more Crinetics Pharmaceuticals, Inc. financial stats to get the full picture.
Today Crinetics Pharmaceuticals, Inc. has the market capitalization of 3.35 B, it has increased by 0.96% over the last week.
No, CRNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CRNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Crinetics Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 290.00 employees. See our rating of the largest employees — is Crinetics Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Crinetics Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Crinetics Pharmaceuticals, Inc. stock shows the buy signal. See more of Crinetics Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Crinetics Pharmaceuticals, Inc. future price: according to them, CRNX price has a max estimate of 80.00 USD and a min estimate of 40.00 USD. Read a more detailed Crinetics Pharmaceuticals, Inc. forecast: see what analysts think of Crinetics Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Crinetics Pharmaceuticals, Inc. EBITDA is −225.29 M USD, and current EBITDA margin is −5.52 K%. See more stats in Crinetics Pharmaceuticals, Inc. financial statements.